Keros Therapeutics (KROS) Equity Ratio (2019 - 2025)

Keros Therapeutics has reported Equity Ratio for 7 years, with the latest figure at 0.9 in Q4 2025.

• For the quarter ending Q4 2025, Equity Ratio fell 3.37% year-over-year to 0.9; the trailing twelve-month figure through Dec 2025 stood at 0.9 (down 3.37% YoY), and the FY2025 full-year result was 0.9, down 3.37% from the prior year.
• Equity Ratio for Q4 2025 stood at 0.9, down from 0.95 in the prior quarter.
• The five-year high for Equity Ratio was 0.97 in Q2 2021, with the low at 0.9 in Q4 2025.
• Historically, Equity Ratio has averaged 0.93 across 5 years, with a median of 0.93 in 2022.
• Annual changes were most pronounced in 2021 — Equity Ratio jumped 334.82% — and 2022, when it slipped 5.08%.
• Keros Therapeutics' Equity Ratio stood at 0.95 in 2021, then retreated by 5.08% to 0.9 in 2022, then decreased by 0.72% to 0.9 in 2023, then climbed by 3.36% to 0.93 in 2024, then retreated by 3.37% to 0.9 in 2025.
• The last three Equity Ratio figures came in at 0.9 (Q4 2025), 0.95 (Q3 2025), and 0.93 (Q2 2025), per Business Quant data.